Synairgen plc Exercise of Options and Total Voting Rights (3689O)
09 Junio 2022 - 9:00AM
UK Regulatory
TIDMSNG
RNS Number : 3689O
Synairgen plc
09 June 2022
Synairgen plc
('Synairgen' or the 'Company')
Exercise of options and total voting rights
Southampton, UK - 9 June 2022: Synairgen plc (LSE: SNG), the
respiratory company developing SNG001, an investigational
formulation for inhalation containing the broad-spectrum antiviral
protein interferon beta, today announces that it shall allot,
concurrent with Admission, 33,150 ordinary shares of 1 penny each
in the capital of the Company ("New Ordinary Shares") following the
exercise of share options by an employee under the Company's
Long-Term Incentive Plan.
Application has been made to the London Stock Exchange for the
New Ordinary Shares, which rank pari passu in all respects with the
Company's existing Ordinary Shares, to be admitted to trading on
AIM which is expected to occur on 16 June 2022 ("Admission").
Following Admission, the Company's total issued share capital
will consist of 201,374,975 Ordinary Shares with one voting right
per share. The Company does not hold any Ordinary Shares in
Treasury. Therefore, following Admission, the total number of
voting rights in the Company will be 201,374,975. This figure may
be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the FCA's Disclosure Guidance and Transparency Rules.
For further enquiries, please contact:
Synairgen plc
Brooke Clarke, Head of Communications
Media@synairgen.com
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate
Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Jessica Hodgson, Namrata Taak
cscsynairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MKC STRATEGIES, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516-606-6545
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on drug
discovery, development and commercialisation. The Company's primary
focus is developing SNG001 (inhaled interferon beta) for the
treatment of severe viral lung infections as potentially the first
host-targeted, broad-spectrum antiviral treatment delivered
directly into the lungs. SNG001 has been granted Fast Track status
from the US Food and Drug Administration (FDA). Founded by
University of Southampton Professors Sir Stephen Holgate, Donna
Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM
(LSE: SNG). For more information about Synairgen, please see
www.synairgen.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRBXGDLLUGDGDC
(END) Dow Jones Newswires
June 09, 2022 10:00 ET (14:00 GMT)
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024